New hope for stomach cancer: immunotherapy combo targets resistant tumors

NCT ID NCT07259473

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial will test a combination of immunotherapy drugs and chemotherapy given before surgery for people with a specific genetic subtype of stomach cancer (dMMR/MSI-H). The study aims to see how well this approach clears the tumor and to understand why some patients do not respond. It will enroll 15 adults in China.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Immune checkpoint inhibitors (PD-1/PD-L1/CTLA-4 antibodies) plus oxaliplatin chemotherapy
What this could lead to: If successful, this could point toward a more effective treatment strategy for Asian patients with this specific type of gastric cancer, potentially increasing the chance of complete tumor removal.
What could go wrong: This is a very small early-phase trial (15 people) and results may not apply to all patients. About half of patients with this cancer type do not respond to immunotherapy, and the study may not uncover why.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma mismatch repair cancer syndrome 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA IMMUNOTHERAPY MISMATCH REPAIR DEFICIENT OR MSI-HIGH SOLID TUMORS

More trials for these conditions

Other studies related to the condition(s) this trial covers.